Ligand Pharmaceuticals Management
Management criteria checks 4/4
Ligand Pharmaceuticals' CEO is Todd Davis, appointed in Dec 2022, has a tenure of 17.75 years. total yearly compensation is $6.22M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $9.08M. The average tenure of the management team and the board of directors is 2 years and 15.1 years respectively.
Key information
Todd Davis
Chief executive officer
US$6.2m
Total compensation
| CEO salary percentage | 10.5% |
| CEO tenure | 2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2yrs |
| Board average tenure | 15.1yrs |
Recent management updates
Recent updates
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
Nov 24Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$45m |
| Jun 30 2024 | n/a | n/a | US$42m |
| Mar 31 2024 | n/a | n/a | US$96m |
| Dec 31 2023 | US$6m | US$650k | US$54m |
| Sep 30 2023 | n/a | n/a | US$21m |
| Jun 30 2023 | n/a | n/a | US$41m |
| Mar 31 2023 | n/a | n/a | US$51m |
| Dec 31 2022 | US$6m | US$49k | -US$5m |
| Sep 30 2022 | n/a | n/a | US$23m |
| Jun 30 2022 | n/a | n/a | US$27m |
| Mar 31 2022 | n/a | n/a | US$45m |
| Dec 31 2021 | US$328k | n/a | US$76m |
| Sep 30 2021 | n/a | n/a | US$68m |
| Jun 30 2021 | n/a | n/a | US$48m |
| Mar 31 2021 | n/a | n/a | US$39m |
| Dec 31 2020 | US$329k | n/a | US$7m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$350k | n/a | US$629m |
| Sep 30 2019 | n/a | n/a | US$594m |
| Jun 30 2019 | n/a | n/a | US$677m |
| Mar 31 2019 | n/a | n/a | US$764m |
| Dec 31 2018 | US$343k | n/a | US$143m |
| Sep 30 2018 | n/a | n/a | US$179m |
| Jun 30 2018 | n/a | n/a | US$120m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$283k | n/a | US$13m |
Compensation vs Market: Todd's total compensation ($USD6.22M) is about average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.
CEO
Todd Davis (63 yo)
2yrs
Tenure
US$6,216,518
Compensation
Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$6.22m | 0.42% $ 9.1m | |
| Chief Financial Officer | 2.1yrs | US$2.45m | 0.12% $ 2.6m | |
| Chief Legal Officer & Secretary | 2.1yrs | US$2.34m | 0.12% $ 2.6m | |
| Senior Vice President of Investments & Business Development | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Director of Corporate Development | no data | no data | no data | |
| Senior Vice President of Biology & Scientific Affairs | 6.9yrs | no data | no data | |
| Senior Vice President of Technical Operations & QA - Capitsol | 6.9yrs | no data | no data | |
| Senior VP & CBO Protein Expression Business | no data | no data | no data | |
| Senior VP of Investments & Head of Clinical Strategy | less than a year | no data | no data | |
| Senior VP of Investment Operation | less than a year | no data | no data | |
| CEO of Pelthos Therapeutics | less than a year | no data | no data |
2.0yrs
Average Tenure
57yo
Average Age
Experienced Management: LGND's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 17.8yrs | US$6.22m | 0.42% $ 9.1m | |
| Independent Chairman | 21.8yrs | US$361.70k | 0.23% $ 4.9m | |
| Independent Director | 13.8yrs | US$329.20k | 0.15% $ 3.2m | |
| Independent Director | 16.3yrs | US$341.70k | 0.15% $ 3.3m | |
| Independent Director | 18.3yrs | US$339.20k | 0.43% $ 9.4m | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 2.5yrs | US$346.70k | 0.022% $ 475.3k | |
| Independent Director | 7.3yrs | US$336.70k | 0.030% $ 645.7k | |
| Independent Director | 1.3yrs | US$467.87k | no data |
15.1yrs
Average Tenure
63.5yo
Average Age
Experienced Board: LGND's board of directors are seasoned and experienced ( 15.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |